Osvaldo Flores - Century Therapeutics CEO Pres
| IPSC Stock | USD 1.30 0.09 7.44% |
Insider
Osvaldo Flores is CEO Pres of Century Therapeutics
| Age | 61 |
| Address | 25 North 38th Street, Philadelphia, PA, United States, 19104 |
| Phone | 267 817 5790 |
| Web | https://www.centurytx.com |
Century Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.209) % which means that it has lost $0.209 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6261) %, meaning that it created substantial loss on money invested by shareholders. Century Therapeutics' management efficiency ratios could be used to measure how well Century Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 26, 2024, Return On Tangible Assets is expected to decline to -0.4. In addition to that, Return On Capital Employed is expected to decline to -0.45. At present, Century Therapeutics' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 195.3 M, whereas Total Assets are forecasted to decline to about 352.6 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Hing Wong | HCW Biologics | 70 | |
| Lisa Miller | Lumos Pharma | N/A | |
| Robert MBA | Eliem Therapeutics | 56 | |
| MBA MD | Eliem Therapeutics | 63 | |
| FACC MD | Milestone Pharmaceuticals | 60 | |
| Bradley JD | Lumos Pharma | 45 | |
| Katherine Taudvin | Scpharmaceuticals | N/A | |
| Peter Rhode | HCW Biologics | 66 | |
| MD BA | Lumos Pharma | 69 | |
| Erin Lavelle | Eliem Therapeutics | 47 | |
| Lori CPA | Lumos Pharma | 40 | |
| Guy Rousseau | Milestone Pharmaceuticals | N/A | |
| David MBA | Seres Therapeutics | 63 | |
| Philippe MBA | Milestone Pharmaceuticals | 62 | |
| FACC FAHA | Milestone Pharmaceuticals | 66 | |
| Richard Hawkins | Lumos Pharma | 75 | |
| Lorenz Muller | Milestone Pharmaceuticals | 60 | |
| Jo PalmerPhillips | Eliem Therapeutics | N/A | |
| Kristin Ainsworth | Seres Therapeutics | N/A | |
| Jeff Nelson | Milestone Pharmaceuticals | 43 | |
| Jeff York | Seres Therapeutics | N/A | |
Management Performance
| Return On Equity | -0.63 | ||||
| Return On Asset | -0.21 |
Century Therapeutics Leadership Team
Elected by the shareholders, the Century Therapeutics' board of directors comprises two types of representatives: Century Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Century. The board's role is to monitor Century Therapeutics' management team and ensure that shareholders' interests are well served. Century Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Century Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Diem, Chief Officer | ||
| Morgan Conn, Chief Officer | ||
| Michael Naso, Senior Engineering | ||
| Nick MD, Senior Development | ||
| Kenneth JD, Head Compliance | ||
| Chad Cowan, Chief Officer | ||
| PharmD MBA, CEO Director | ||
| Adrienne Farid, COO Development | ||
| Shane Williams, Chief Officer | ||
| Gregory Russotti, Chief Officer | ||
| Douglas CPA, Senior Secretary | ||
| Mark Wallet, Head VP | ||
| Luis Borges, Chief Officer | ||
| Michael MD, Chief Officer | ||
| Osvaldo Flores, CEO Pres | ||
| Hyam MD, President Development | ||
| Katja Buhrer, Head SVP |
Century Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Century Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.63 | ||||
| Return On Asset | -0.21 | ||||
| Operating Margin | (43.98) % | ||||
| Current Valuation | (40.63 M) | ||||
| Shares Outstanding | 85.03 M | ||||
| Shares Owned By Insiders | 28.36 % | ||||
| Shares Owned By Institutions | 59.00 % | ||||
| Number Of Shares Shorted | 3.52 M | ||||
| Price To Earning | 86.08 X | ||||
| Price To Book | 0.53 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Century Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Century Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Century Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Century Therapeutics Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Century Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Century Stock refer to our How to Trade Century Stock guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Century Therapeutics. If investors know Century will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Century Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.83) | Revenue Per Share 0.037 | Quarterly Revenue Growth 4.345 | Return On Assets (0.21) | Return On Equity (0.63) |
The market value of Century Therapeutics is measured differently than its book value, which is the value of Century that is recorded on the company's balance sheet. Investors also form their own opinion of Century Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Century Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Century Therapeutics' market value can be influenced by many factors that don't directly affect Century Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Century Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Century Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Century Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.